CLL Microlearning Series – Video #5: Managing Common Side Effects
Managing Common Side Effects
BTK inhibitors like zanubrutinib are effective and generally well-tolerated, but many patients experience early, non-dangerous side effects that can impact comfort and adherence.
In this video, an APP specializing in CLL reviews the most common symptoms patients report and shares practical strategies clinicians can use to support management and keep patients on therapy.
In This Video, You’ll Learn:
- The most common BTK-related side effects, including bruising, diarrhea, myalgias, arthralgias, and rashes
- Why these symptoms often appear early in therapy and how they typically improve over time
- Practical counseling tips: antidiarrheals, magnesium supplementation, stretching, and topical steroids
- The importance of early check-ins to assess new symptoms and reinforce adherence
- How to counsel patients on holding zanubrutinib around procedures to reduce bleeding risk
More from this series
CLL Microlearning: Setting the Stage for Treatment Decisions in CLL
This segment outlines the key patient and disease characteristics that inform when—and how—to approach therapy in a thoughtful, individualized way.
January 12, 2026
CLL Microlearning: Considerations for 1st Line Therapy
This short module highlights the practical, real-world cues that signal true disease progression—ensuring therapy begins at the appropriate time and for the right reasons. An APP specializing in CLL walks through how to interpret clinical symptoms, lab trends, and iwCLL criteria in everyday practice.
November 13, 2025
CLL Microlearning: Why Zanubrutinib is a Meaningful Option
This segment highlights why zanubrutinib has emerged as a meaningful choice in frontline and relapsed CLL, especially for older adults and those with cardiovascular comorbidities who may be more vulnerable to off-target toxicities.
November 13, 2025
CLL Microlearning: Practical Aspects of Prescribing Zanubrutinib
This video covers the key practical details clinicians should know when prescribing zanubrutinib. As a second-generation BTK inhibitor, it offers effective disease control with a flexible dosing schedule that can be tailored to patient needs.
November 13, 2025
CLL Microlearning: Zanubrutinib’s Cardiovascular Profile
In this video, an APP specializing in CLL explains how zanubrutinib compares to other BTK inhibitors and outlines practical steps clinicians can take to evaluate and manage cardiovascular risk.
November 13, 2025
CLL Microlearning: Empowering Patients Through Choice and Communication
This video outlines how APPs can use communication and side-effect counseling to support consistent, long-term adherence to zanubrutinib.
November 13, 2025
CLL Microlearning: Personal Insights and Practice-Based Learning
In this video, an APP specializing in CLL reflects on how newer options—particularly zanubrutinib—support more individualized care by balancing efficacy, safety, and patient preferences.
November 13, 2025